American Diabetes Association calls on Congress to hold hearings on insulin prices
The American Diabetes Association's board of directors is calling on Congress to hold hearings to investigate dramatic increases in insulin prices and to take action to ensure that people have affordable access to the essential drug.
In a resolution, the board asked politicians to examine the entire supply chain for insulin, ranging from the three drug companies that dominate the market to health insurers and the companies they hire to bargain for drug prices. They also called on the companies that make and provide insulin to patients to increase the transparency of pricing, which could help explain why prices have risen and which companies benefit.
The American Diabetes Association said Congress should “take action to ensure that all people who use insulin have affordable access to the insulin they need,” noting that the cost of treating diabetes has “skyrocketed” and insulin prices in Europe are about a sixth of the price in the United States. The association also launched a petition, “Stand up for affordable insulin,” asking people to sign on to let companies and Congress know that greater transparency and attention is needed to soaring insulin prices.
Robert Ratner, the chief scientific and medical officer for the organization said that the move was a follow-up to its February call for greater transparency and other moves by health care companies that could ensure the affordability of insulin.
"Nothing has changed and some things have appeared to get worse," Ratner said. "We have had disucssisons with industry -- the pharma companies are very much aware of t Continue reading